This is an early-stage safety study testing a new type of personalized immune cell therapy called BAFFR-CAR T cells in adults with B-cell acute lymphoblastic leukemia that has come back or stopped responding to standard treatments. The main goals are to find a safe dose and under…
Phase: PHASE1 • Sponsor: PeproMene Bio, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC